ATE531383T1 - Therapeutische verwendung eines wachstumsfaktors, metrnl - Google Patents

Therapeutische verwendung eines wachstumsfaktors, metrnl

Info

Publication number
ATE531383T1
ATE531383T1 AT09776234T AT09776234T ATE531383T1 AT E531383 T1 ATE531383 T1 AT E531383T1 AT 09776234 T AT09776234 T AT 09776234T AT 09776234 T AT09776234 T AT 09776234T AT E531383 T1 ATE531383 T1 AT E531383T1
Authority
AT
Austria
Prior art keywords
metrnl
growth factor
therapeutic use
neuroprotective
genes
Prior art date
Application number
AT09776234T
Other languages
English (en)
Inventor
Jesper Jyrgensen
Lone Fjord-Larsen
Lars Wahlberg
Nuno Andrade
Teit Johansen
Original Assignee
Nsgene As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nsgene As filed Critical Nsgene As
Application granted granted Critical
Publication of ATE531383T1 publication Critical patent/ATE531383T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT09776234T 2008-07-24 2009-07-07 Therapeutische verwendung eines wachstumsfaktors, metrnl ATE531383T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8331608P 2008-07-24 2008-07-24
DKPA200801036 2008-07-24
PCT/DK2009/050165 WO2010009732A1 (en) 2008-07-24 2009-07-07 Therapeutic use of a growth factor, metrnl

Publications (1)

Publication Number Publication Date
ATE531383T1 true ATE531383T1 (de) 2011-11-15

Family

ID=41314584

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09776234T ATE531383T1 (de) 2008-07-24 2009-07-07 Therapeutische verwendung eines wachstumsfaktors, metrnl

Country Status (9)

Country Link
US (4) US8334264B2 (de)
EP (1) EP2195013B1 (de)
JP (1) JP5616888B2 (de)
CN (1) CN102164611B (de)
AT (1) ATE531383T1 (de)
AU (1) AU2009273600B2 (de)
CA (1) CA2730710C (de)
DK (1) DK2195013T3 (de)
WO (1) WO2010009732A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009732A1 (en) 2008-07-24 2010-01-28 Nsgene A/S Therapeutic use of a growth factor, metrnl
ES2584068T3 (es) 2010-10-01 2016-09-23 Nsgene A/S Uso de meteorina para el tratamiento de alodinia, hiperalgesia, dolor espontáneo y dolor fantasma
WO2013034157A1 (en) 2011-09-05 2013-03-14 Nsgene A/S Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain
US10717992B2 (en) 2013-01-25 2020-07-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for regulating thermogenesis and muscle inflammation using metrnl and metrn
WO2014183207A1 (en) * 2013-05-17 2014-11-20 Exerkine Corporation Therapeutic method of treating metabolic syndrome
WO2015062167A1 (zh) * 2013-10-29 2015-05-07 中国人民解放军第二军医大学 Metrnl蛋白在制备降血脂降血糖药物中的应用
CN103536903B (zh) * 2013-10-29 2015-04-15 中国人民解放军第二军医大学 Metrnl蛋白在制备降血脂药物方面的应用
CN103536904B (zh) * 2013-10-29 2015-02-18 中国人民解放军第二军医大学 Metrnl蛋白在制备降血糖药物方面的应用
US11434501B2 (en) 2014-08-28 2022-09-06 Board Of Trustees Of Michigan State University Sprr1A as a genetic target for treating neurodegenerative diseases
US9687483B2 (en) * 2015-01-26 2017-06-27 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
CN104977415A (zh) * 2015-03-09 2015-10-14 中国人民解放军第二军医大学 Metrnl蛋白作为炎症性肠病诊断血清标志物的应用及其试剂盒
CN104808004B (zh) * 2015-05-06 2017-03-01 中国人民解放军第二军医大学 Metrnl蛋白作为结肠癌诊断标志物的应用及试剂盒
KR101586054B1 (ko) * 2015-11-20 2016-01-21 고려대학교 산학협력단 메테오린-유사체 (meteorin-like)를 포함하는 유방암의 예방 또는 치료용 조성물
CN107088223B (zh) * 2016-02-17 2020-07-07 中国人民解放军第二军医大学 Metrnl蛋白或基因在治疗内皮功能受损中的应用
DE102016204700A1 (de) 2016-03-22 2017-09-28 Universität Rostock Rekombinante Herstellung von Subfatin
CN107537025B (zh) * 2016-06-23 2020-01-10 上海风劲生物医药科技有限公司 Metrnl蛋白或基因在调节抗菌肽表达中的应用
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
WO2018165183A1 (en) * 2017-03-06 2018-09-13 Tactus Therapeutics, Inc. Abuse deterrent opioid formulations
WO2019014322A1 (en) 2017-07-11 2019-01-17 BioAxone BioSciences, Inc. KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
SG11202003609VA (en) * 2017-10-25 2020-05-28 Nouscom Ag Eukaryotic cell line
CN110227146A (zh) * 2018-03-06 2019-09-13 上海风劲生物医药科技有限公司 Metrnl蛋白或基因在防治认知障碍方面的应用
CN112638370A (zh) 2018-09-12 2021-04-09 霍夫耳科研究所 用于治疗耳蜗植入手术引起的听力损失的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585368B1 (de) 1991-04-25 1997-08-06 Brown University Research Foundation Implantierbare, biokompatible immunisolator-trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
DK0639225T3 (da) * 1992-04-30 2003-02-17 Innogenetics Nv Nye polypeptider og peptider, nucleinsyrer, der koder for dem, og deres anvendelse i området tumorterapi, inflammation eller immunologi
EP0802800B1 (de) 1993-08-12 2002-06-12 Neurotech S.A. Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
AU7452300A (en) 1999-10-01 2001-05-10 Kyowa Hakko Kogyo Co. Ltd. Shear stress-response dna
WO2001039786A2 (en) 1999-11-30 2001-06-07 Innogenetics N.V. New uses of suppressive macrophage activation factors
CA2393002A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2395676A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
EP1572987A4 (de) 2000-02-03 2005-11-30 Nuvelo Inc Neuartige nukleinsäure und polypeptide
AU2001255668A1 (en) 2000-05-02 2001-11-12 Human Genome Sciences, Inc. 29 human secreted proteins
AU2002364968A1 (en) 2001-12-21 2003-09-02 Diadexus, Inc. Compositions and methods relating to hepatic specific genes and proteins
AU2003294217A1 (en) 2002-08-29 2004-05-04 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
US20050208500A1 (en) 2003-03-04 2005-09-22 Erlander Mark G Signatures of ER status in breast cancer
CN1950397B (zh) 2004-03-30 2012-05-16 Ns基因公司 生长因子NsG33的治疗用途
WO2006110593A2 (en) * 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
WO2010009732A1 (en) 2008-07-24 2010-01-28 Nsgene A/S Therapeutic use of a growth factor, metrnl
ES2584068T3 (es) 2010-10-01 2016-09-23 Nsgene A/S Uso de meteorina para el tratamiento de alodinia, hiperalgesia, dolor espontáneo y dolor fantasma
WO2013034157A1 (en) 2011-09-05 2013-03-14 Nsgene A/S Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain

Also Published As

Publication number Publication date
US20110112035A1 (en) 2011-05-12
US20160045564A1 (en) 2016-02-18
CA2730710C (en) 2021-06-08
WO2010009732A1 (en) 2010-01-28
CN102164611B (zh) 2015-01-07
EP2195013A1 (de) 2010-06-16
JP2011528558A (ja) 2011-11-24
CA2730710A1 (en) 2010-01-28
EP2195013B1 (de) 2011-11-02
US8334264B2 (en) 2012-12-18
JP5616888B2 (ja) 2014-10-29
US20170333526A1 (en) 2017-11-23
US9068015B2 (en) 2015-06-30
US20130267464A1 (en) 2013-10-10
AU2009273600A1 (en) 2010-01-28
DK2195013T3 (da) 2012-02-06
US9675669B2 (en) 2017-06-13
US10034918B2 (en) 2018-07-31
CN102164611A (zh) 2011-08-24
AU2009273600B2 (en) 2013-04-18
HK1145070A1 (en) 2011-04-01

Similar Documents

Publication Publication Date Title
ATE531383T1 (de) Therapeutische verwendung eines wachstumsfaktors, metrnl
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
TW200833692A (en) Triazolopyridazine protein kinase modulators
PH12012502215A1 (en) Anti-fgfr2 antibodies
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
UA107812C2 (xx) ДВОЗАМІЩЕНІ ОКТАГІДРОПІРОЛО$3,4-с]ПІРОЛИ ЯК МОДУЛЯТОРИ ОРЕКСИНОВИХ РЕЦЕПТОРІВ
DE602006017071D1 (de) Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
EA201490697A1 (ru) Белки с двойной функцией для лечения метаболических расстройств
MX391154B (es) Compuestos con actividad anticancer
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
EA201170149A1 (ru) Новые аналоги инсулина пролонгированной активности
MY184241A (en) Human antibodies to gfr?3 and methods of use thereof
GB2471588A (en) Therapeutic peptidomimetic macrocycles
MX2009003704A (es) Inhibidores de cinasa utiles para el tratamiento de enfermedades mileoproliferativas y otras enfermedades proliferativas.
WO2008080062A3 (en) Equine airway disorders
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
HRP20192130T1 (hr) Kombinacijska terapija za liječenje pacijenata s neurološkim poremećajima i moždanim udarom
MX2011012311A (es) Marcadores geneticos asociados con la respuesta al interferon alfa.
MY159551A (en) High affinity human antibodies to human protease-activated receptor-2
EP4124346A3 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten
EP2465923A3 (de) Verfahren zur Verwendung von Zellen aus Fettgewebe zur Behandlung kardiovaskulärer Erkrankungen
MX2009006672A (es) Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
MX2009012969A (es) Grelina no acilada como agente terapeutico en el tratamiento de trastornos metabolicos.
ATE430763T1 (de) Therapeutische verwendung des wachstumsfaktors nsg33